AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02613988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic susceptibility contrast MRI
Description: dual echo EPI sequence
Study NCT01627223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.
Study NCT01627223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: •Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.
Study NCT01136213 — intervention group
Intervention type: RADIATION
Intervention: PET (Positron Emission Tomography) Study
Description: 5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
Study NCT01136213 — intervention group
Intervention type: OTHER
Intervention: Brain MRI (magnetic resonance imaging)
Description: A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
Study NCT01136213 — intervention group
Intervention type: DRUG
Intervention: Fluoxétine / Placebo
Description: The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
Study NCT03460613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP diet
Description: Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
Study NCT04445688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036
Description: Oral administration before bed
Study NCT04445688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Oral administration before bed
Study NCT04445688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration before bed
Study NCT01256008 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Management
Description: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible.
Study NCT02114216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic mucosal biopsy
Description: endoscopic mucosal biopsy was undertaken for every participant.
Study NCT02114216 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: endoscopic mucosal biopsy
Description: endoscopic mucosal biopsy was undertaken for every participant.
Study NCT01350583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3)
Description: Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
Study NCT03056885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional One-Lung Ventilation
Description: Vt 10 ml/kg
Study NCT03056885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective One-lung ventilation
Description: Vt 5 ml/kg
Study NCT03333447 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT01795209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit
Study NCT01795209 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit
Study NCT02261064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine high dose
Study NCT01795209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue laser
Description: In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3
Study NCT02261064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese meal
Study NCT01667497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Study NCT01667497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02977364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Study NCT01795209 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Rescue laser
Description: In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3
Study NCT03169712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for PTSD
Description: Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
Study NCT03169712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for PTSD
Description: Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
Study NCT03169712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy
Description: IRT protocol published by Nappi and collaborators (2010)
Study NCT03466437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass-fiber post and composite resin restoration
Description: Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
Study NCT03466437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass-fiber post and metalceramic crown
Description: Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Audit-Feedback, Stratified by Race and Ethnicity
Description: Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider Audit-Feedback, Stratified by Race and Ethnicity
Description: Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement Standardization
Description: All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures.
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Measurement Standardization
Description: All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures.
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System Level Leadership Intervention
Description: This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase.
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Team Intervention
Description: The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Referral
Description: As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants
Study NCT02674464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialist Care Consultation
Description: As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care
Study NCT01926951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surround Sound Externally Focused Therapeutic Ultrasound
Description: Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
Study NCT02281227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin compression
Description: skin compression with an indicator for determination of needle entry point
Study NCT04153981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study NCT00783835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Methylphenidate
Description: Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
Study NCT03256669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical incision
Description: exploration through umbilical incision
Study NCT03764319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-protective ventilator settings
Description: 4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume > 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
Study NCT03764319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ventilator settings
Description: 12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
Study NCT02168634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins
Description: 5U botulinum toxin in 1c.c. normal saline, local injection
Study NCT03244384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02168634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1cc normal saline, local injection
Study NCT00772291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: pregabalin 150-600mg/day during 8 weeks
Study NCT00772291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo drug during 8 weeks
Study NCT03244384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02937272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally
Study NCT04444102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga-based stretching
Description: Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators.
Study NCT02900339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
Study NCT00807378 — intervention group
Intervention type: OTHER
Intervention: LUMBAR PUNCTURE
Description: LUMBAR PUNCTURE FFOR CSF COLLECTION
Study NCT00425295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Simulation Training
Description: Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
Study NCT00971230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: emtricitabine/tenofovir disoproxil fumarate
Study NCT00971230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02266004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
Study NCT03466437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cast-metal post and metalceramic crown
Description: Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
Study NCT00425295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Simulation Training
Description: Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
Study NCT03146013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MP Diagnostics HTLV Blot 2.4
Description: HTLV I/II Confirmation and Differentiation
Study NCT02266004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: locomotor training
Description: An individualized dual-task walking program for approximately 30 minutes.
Study NCT00827632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose formulation
Description: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
Study NCT04664712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tendisulfur Pro
Description: Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
Study NCT01666860 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior Lumbar Interbody Fusion procedure
Study NCT03251872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets
Study NCT01085604 — intervention group
Intervention type: OTHER
Intervention: Core Stabilization
Description: The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning.
Study NCT00126672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Study NCT02032186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium citrate
Description: Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
Study NCT02032186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium citrate
Description: Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
Study NCT04432467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous adipose tissue-derived mesenchymal stem cells